Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + anlotinib
- Development stage
- Phase 2
- Lead developer
- Jilin Provincial Cancer Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niraparib + anlotinib is a combination therapy being investigated for the treatment of small cell lung cancer (SCLC), particularly in the maintenance setting or for relapsed/refractory cases. Niraparib is an orally active inhibitor of PARP-1 and PARP-2, which are enzymes involved in DNA repair; by inhibiting PARP, it induces synthetic lethality in cells with DNA repair deficiencies, especially those with homologous recombination deficiencies. Anlotinib is a multi-targeted tyrosine kinase inhibitor that suppresses tumor angiogenesis and growth by inhibiting VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. The combination aims to synergistically inhibit tumor progression by simultaneously targeting DNA repair mechanisms and the tumor microenvironment/angiogenesis. Clinical trials, such as those led by Jilin Province Cancer Hospital, explore this regimen's efficacy and safety in SCLC patients who have failed prior systemic therapies.
- Brand names
- Fukanghua
- Other names
- niraparib and anlotinibanlotinib plus niraparib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on niraparib + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + anlotinib.